Medical Design and Outsourcing New research backs iRhythm’s Zio XT against Holter, event monitors
- iRhythm Technologies (NSDQ:IRTC) announced today that a study demonstrated the superiority of its Zio XT compared to other cardiac monitors.
- San Francisco-based iRhythm’s KP-Rhythm2 study — published in the American Journal of Cardiology — examined the efficiency of Zio XT, Holter monitors and event monitors with the aim of assessing diagnostic yield, outcomes and resource utilization by monitoring modality in individuals without previously documented atrial fibrillation (AFib) or atrial flutter (AFL).
- According to a news release, while earlier studies have proven Zio XT to be better than Holter and event monitors for detecting arrhythmias, the KP-Rhythm2 study (led by Kaiser Permanente and supported by a research grant from iRhythm) is the first to specifically address the Zio XT patch against a 30-day event monitor yielding similar diagnostic yield for AFib and AFL in a general population of adults without known prior AFib/AFL
Continue reading the full article here.